New drug combo for drug-resistant tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed case of multi-drug resistant or rifampicin-resistant tuberculosis, with a positive lab test in the last 2 months.
- You are 18 years old or older.
- You have not used bedaquiline, delamanid, or linezolid before, or have used them for less than 4 weeks total.
- You have a positive sputum culture for tuberculosis at the start of the study and haven't had anti-tuberculosis treatment in the past month.
- You do not have serious heart problems, nerve damage, or liver issues, and your heart rhythm test (QTcF) is under 450 milliseconds.
- You agree to follow the treatment plan and attend all follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This study tests a new oral medication combination (quabodepistat with other drugs) for people with drug-resistant pulmonary TB. It aims to find a shorter, safer, and more effective treatment.
This study tests a very short treatment for active lung TB in people aged 65 and older. The goal is to see if a short course of medicines can effectively cure TB without side effects.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.